Posts Tagged ‘Nasodine’
Firebrick Consultant to drive Pharmacy Distribution in Singapore
Firebrick Pharma (ASX:FRE) is pleased to announce that it has executed a consulting agreement (Agreement) with Keith Shortall, a former senior executive of Johnson & Johnson Consumer Health Asia-Pacific (J&J Consumer Health APAC). The primary goal of the Agreement is to establish pharmacy distribution for Nasodine in Singapore. Secondary objectives include evaluating potential distribution to…
Nasodine European Marketing Application filed and passed validation
Firebrick Pharma (ASX:FRE) is pleased to announce that it has filed a Marketing Authorisation Application (“MAA”) in Europe for the approval of Nasodine® Nasal Spray as a nasal antiseptic. The MAA has successfully passed validation and has now entered the evaluation phase. The application was filed via a decentralised procedure, where one EU member state,…
New agreement allows Nasodine launch in Philippines
Firebrick Pharma is pleased to announce that it has executed an amended agreement with its existing marketing partner in the Philippines, S.V. More Pharma Corporation (SV More). Under the amended agreement, SV More will have the right to manufacture Nasodine® Nasal Spray (“Nasodine”) in the Philippines, rather than import the product from Australia. This will…
Firebrick Launches Nasodine in Singapore via Nasodine-sg.com
Firebrick Pharma Limited (ASX:FRE) is proud to announce that its product, Nasodine® Nasal Spray, is now available for sale in Singapore. Customers will be able to order the product through Firebrick’s new website dedicated to support Singapore sales: www.nasodine-sg.com In Singapore, Nasodine is classified as a topical antiseptic and does not require approval or licensing…
Firebrick Raises $800,000 via Placement
Firebrick Pharma Limited (ASX: FRE) is pleased to announce that it has received binding commitments for a placement of $800,000, comprising 16 million shares at $0.05 per share (Placement). GZ Family Holdings Pty Ltd, an existing substantial holder in Firebrick, has committed to take up 14 million shares ($700,000 of the Placement) and 2 million…
Firebrick Pharma launches Nasodine in the US via Nasodine.com
Firebrick Pharma (ASX:FRE) has launched its nasal spray product, Nasodine® Nasal Spray in the United States, the first country in the world where the product has become commercially available.
Nasodine Phase 2 COVID-19 Trial Results Published
The Company is now advanced in our plans to introduce Nasodine in at least one international market.
Nasodine COVID-19 patent granted
HIGHLIGHTS • Patent now granted in US, Australia and South Africa • Patent supports proposed nasal disinfection use of Nasodine Firebrick Pharma is pleased to announce that our patent covering the use of Nasodine® Nasal Spray in COVID-19 has now been granted in South Africa. The patent has previously been granted in the US and Australia…
Nasal disinfection as a front-line defence in future pandemics
Recently, Professor Peter Friedland presented at the Australian Military Medical Association conference (12 – 15 October 2023), with the title of his presentation being: “Nasal Disinfection as a Front-line Defence in Future Pandemics”. Read the published abstract here To view the full presentation, please click here Disclosure: the presentation is the view of the presenter…
Update on Nasodine Trial and Forward Plans
Firebrick Pharma Limited announced that the independent preliminary investigation into the Phase 3 trial results of Nasodine Nasal Spray (“Nasodine”) (refer ASX announcement 13 September 2023) has not revealed any systematic error or other data issue that could explain or disclaim the reported results. The preliminary investigation phase has now been closed to avoid additional…
Firebrick Phase 3 Trial fully recruited with 500 subjects
Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine® Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by…